Dopamine Receptor D4 (DRD4) Genotyping
- Influencing the target dose of methylphenidate treatment for patients with attention deficit hyperactivity disorder
- Determining possible cause for poor response to methylphenidate in treated patients with attention deficit/hyperactivity disorder
The presence of the DRD4 7R allele, alone or in combination with the SLC6A4 long/long promotor polymorphism of the serotonin transporter, is associated with lower responsiveness of ADHD to methylphenidate (e.g., Ritalin, Concerta), the main treatment for ADHD. Methylphenidate dosage may have to be increased to effectively treat individuals with the DRD4 7R allele.
The effect of other repeat numbers has not been defined and, if other alleles than the 4R and 7R are present, caution should be exercised in using methylphenidate to treat ADHD because the impact of these alleles on treatment response is not known.
Attempts to find an association between DRD4 genotype and the variability of response to antipsychotic drugs, especially clozapine, have been largely unsuccessful or have yielded conflicting results.
Genotypes are reported as the number of repeat copies per allele. The 4-repeat allele is considered wild-type (4R/4R)
Whole blood (EDTA), Saliva, Or Buccal swab.
Stability
- Ambient: 5 days
- Refrigerated: 7 days
- Hum Genet. 1996 Jul;98(1): 91-101. [PMID: 8682515]
- J Child Adolesc Psychopharmacol. 2004;14(4): 564-574 [PMID: 15662148]
- Rev Med Chil. 2003 Feb;131(2):135-43. [PMID: 12708251]
- Biol Psychiatry. 2005 Jun 1;57(11):1313-23. [PMID: 15950004]